Movement Alert｜Hengrui Medicine Falls 3.02% in Regular Trading, Broad Pharma Sector Sell-Off Amid Geopolitical Headwinds

Market Focus06-22

On June 22, Hengrui Medicine (01276.HK) declined 3.02% in regular trading, trading at HK$52.95/share, with turnover of HK$66.36 million. The decline came amid a broad sell-off across the Hong Kong-listed pharmaceuticals sector.

The downturn aligns with ongoing macro headwinds identified by JPMorgan in a June 16 report, which noted that Hengrui's stock had fallen approximately 40% from its 52-week high. The bank attributed the weakness primarily to escalating US-China geopolitical tensions and institutional de-risking from H-share healthcare exposure, rather than any deterioration in company fundamentals. JPMorgan upgraded Hengrui to Overweight with a HK$68 target price, citing undervalued earnings trajectory and pipeline expansion.

Within the Pharmaceuticals sector, declines were broad-based. CSPC Pharma fell 3.77%, Hansoh Pharma fell 1.74%, SBP Group fell 4.59%, United Lab fell 3.39%, and Luye Pharma fell 5.05%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135717515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135717515","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Falls 3.02% in Regular Trading, Broad Pharma Sector Sell-Off Amid Geopolitical Headwinds","media":"Market Focus","content":"<p><p>On June 22, Hengrui Medicine (01276.HK) declined 3.02% in regular trading, trading at HK$52.95/share, with turnover of HK$66.36 million. The decline came amid a broad sell-off across the Hong Kong-listed pharmaceuticals sector.</p><p>The downturn aligns with ongoing macro headwinds identified by JPMorgan in a June 16 report, which noted that Hengrui's stock had fallen approximately 40% from its 52-week high. The bank attributed the weakness primarily to escalating US-China geopolitical tensions and institutional de-risking from H-share healthcare exposure, rather than any deterioration in company fundamentals. JPMorgan upgraded Hengrui to Overweight with a HK$68 target price, citing undervalued earnings trajectory and pipeline expansion.</p><p>Within the Pharmaceuticals sector, declines were broad-based. CSPC Pharma fell 3.77%, Hansoh Pharma fell 1.74%, SBP Group fell 4.59%, United Lab fell 3.39%, and Luye Pharma fell 5.05%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Falls 3.02% in Regular Trading, Broad Pharma Sector Sell-Off Amid Geopolitical Headwinds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Falls 3.02% in Regular Trading, Broad Pharma Sector Sell-Off Amid Geopolitical Headwinds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, Hengrui Medicine (01276.HK) declined 3.02% in regular trading, trading at HK$52.95/share, with turnover of HK$66.36 million. The decline came amid a broad sell-off across the Hong Kong-listed pharmaceuticals sector.</p><p>The downturn aligns with ongoing macro headwinds identified by JPMorgan in a June 16 report, which noted that Hengrui's stock had fallen approximately 40% from its 52-week high. The bank attributed the weakness primarily to escalating US-China geopolitical tensions and institutional de-risking from H-share healthcare exposure, rather than any deterioration in company fundamentals. JPMorgan upgraded Hengrui to Overweight with a HK$68 target price, citing undervalued earnings trajectory and pipeline expansion.</p><p>Within the Pharmaceuticals sector, declines were broad-based. CSPC Pharma fell 3.77%, Hansoh Pharma fell 1.74%, SBP Group fell 4.59%, United Lab fell 3.39%, and Luye Pharma fell 5.05%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1135717515","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135717515","pubTimestamp":1782095402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, Hengrui Medicine (01276.HK) declined 3.02% in regular trading, trading at HK$52.95/share, with turnover of HK$66.36 million. The decline came amid a broad sell-off across the Hong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动向提示|恒瑞医药常规交易跌3.02%地缘政治逆风下医药板块遭广泛抛售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On June 22, Hengrui Medicine (01276.HK) declined 3.02% in regular trading, trading at HK$52.95/share, with turnover of HK$66.36 million. The decline came amid a broad sell-off across the Hong Kong-listed pharmaceuticals sector.The downturn aligns with ongoing macro headwinds identified by JPMorgan in a June 16 report, which noted that Hengrui's stock had fallen approximately 40% from its 52-week high. The bank attributed the weakness primarily to escalating US-China geopolitical tensions and institutional de-risking from H-share healthcare exposure, rather than any deterioration in company fundamentals. JPMorgan upgraded Hengrui to Overweight with a HK$68 target price, citing undervalued earnings trajectory and pipeline expansion.Within the Pharmaceuticals sector, declines were broad-based. CSPC Pharma fell 3.77%, Hansoh Pharma fell 1.74%, SBP Group fell 4.59%, United Lab fell 3.39%, and Luye Pharma fell 5.05%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135717515","isCrawlerRequest":true}